Pharma BD Deal Intelligence
Bayer AG's ~$600M buyout of BlueRock Therapeutics' remaining 60% stake gave it full ownership of the cell-therapy pioneer, doubling down on regenerative medicine as a franchise bet rather than a partnered asset.
Bayer to acquire BlueRock Therapeutics for up to $600M with cell therapy pipeline in mind including Parkinson disease candidate
Bayer acquires BlueRock Therapeutics in cell therapy move gaining full rights to proprietary CELL GENE iPSC platform technology
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Bayer acquired remaining 60% stake in BlueRock Therapeutics for ~$600M.
960K US cases/yr · $12.0B Global Heart Failure Therapeutics (2024) · ~50% 5-Year Survival Rate
Heart failure affects 6.7 million Americans with ~960,000 new cases annually. Despite advances with SGLT2 inhibitors and sacubitril/valsartan, 5-year mortality remains ~50%. Cell therapy using iPSC-derived cardiomyocytes aims to regenerate damaged myocardium.
BlueRock/Bayer's BRT-HF01 uses iPSC-derived cardiomyocytes to replace damaged heart tissue. The approach is in early preclinical stages. Competing regenerative approaches include Novo Nordisk's engineered heart cells and various stem cell programs. The field has been challenged by difficulty in engraftment and arrhythmia risk.
90K US cases/yr · $6.6B Global PD Therapeutics (2024) · $82.2B US Economic Burden (2024)
Parkinson's disease is the second most common neurodegenerative disorder, affecting nearly 1 million Americans with ~90,000 new diagnoses per year (50% higher than prior estimates). Cell therapy approaches using iPSC-derived dopaminergic neurons represent a potential disease-modifying strategy.
BlueRock's bemdaneprocel (BRT-DA01) is a first-in-class iPSC-derived cell therapy for PD. Phase I data showed safety and engraftment. Competitors include Aspen Neuroscience (autologous iPSC) and UCSF academic programs. The cell therapy approach aims to replace lost dopaminergic neurons rather than symptomatic management.
Bayer AG completed its acquisition of BlueRock Therapeutics for $600M. Bayer acquired remaining 60% stake in BlueRock Therapeutics for ~$600M.
Significant transaction at $600M. Bayer acquired remaining 60% stake in BlueRock Therapeutics for ~$600M.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / BlueRock Therapeutics (this deal) | 2002 | $600M | 79 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
| Bayer AG / Asklepios BioPharmaceuticals | 2020 | $2.0B | 49 |
← Browse all deals · How we score deals
More: 2002 deals · Bayer AG deals · Cardiovascular deals